Oxford, UK – 13 December 2021: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Group”), a leading gene and cell therapy group, today announces that it has signed a new Licence and Supply Agreement (“LSA”) with Arcellx, Inc. (“Arcellx”), a Gaithersburg MD.-based biotechnology company developing novel, adaptive and controllable cell therapies for the treatment of patients with cancer and autoimmune diseases. The LSA grants Arcellx a non-exclusive licence to Oxford Biomedica’s LentiVector® platform for its application in select Arcellx CAR-T programmes and puts in place a three-year Clinical Supply Agreement.
Under the terms of the LSA, Oxford Biomedica will receive payments related to the development and manufacturing of lentiviral vectors for use in clinical trials. Additionally, the agreement allows for payments to the Group for the manufacture and supply of lentiviral vectors for commercial use.
This partnership with a leader in the CAR-T field builds on the longstanding partnerships with Novartis and Bristol Myers Squibb, as well as the more recently announced partnership with Beam Therapeutics.
John Dawson, Chief Executive Officer of Oxford Biomedica, said: “Arcellx is one of the leading next-generation CAR-T developers deploying a wide range of innovative technologies to bring innovative CAR-T products into development. We are proud to be working with a leader in the field of CAR-T that shares our vision of delivering cell and gene therapies to save lives. This is yet another valuable opportunity for our LentiVector® platform to support innovative product development of CAR-T products further highlighting Oxford Biomedica’s position as a partner of choice.”
Rami Elghandour, Chairman and CEO of Arcellx said: “We look forward to leveraging Oxford Biomedica’s renowned LentiVector® platform technology, and their industry-leading development and GMP manufacturing expertise in the clinical and commercial development of our CAR-T programmes.”
Oxford Biomedica plc: T: +44 (0)1865 783 000 / E: email@example.com
John Dawson, Chief Executive Officer
Stuart Paynter, Chief Financial Officer
Sophia Bolhassan, Head of Investor Relations
Consilium Strategic Communications: T: +44 (0)20 3709 5700
Mary-Jane Elliott / Matthew Neal
About Oxford Biomedica
Oxford Biomedica (LSE:OXB) is a leading, fully integrated, gene and cell therapy group focused on developing life changing treatments for serious diseases. Oxford Biomedica and its subsidiaries (the “Group”) have built a sector leading lentiviral vector delivery platform (LentiVector®), which the Group leverages to develop in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, CNS disorders and liver diseases. The Group has also entered into a number of partnerships, including with Novartis, Bristol Myers Squibb, Sio Gene Therapies, Orchard Therapeutics, Santen, Beam Therapeutics and Boehringer Ingelheim, through which it has long-term economic interests in other potential gene and cell therapy products. Additionally, the Group has signed a 3-year master supply and development agreement with AstraZeneca for large-scale manufacturing of the adenoviral based COVID-19 vaccine candidate, AZD1222. Oxford Biomedica is based across several locations in Oxfordshire, UK and employs more than 740 people. Further information is available at www.oxb.com
About Arcellx, Inc.
Arcellx is a clinical-stage biopharmaceutical company developing adaptive and controllable cell therapies for the treatment of patients with cancer and autoimmune diseases. The Arcellx vision is to utilize our novel proprietary platform to bring superior cell therapies to more patients through the care of academic and community practices worldwide. More information can be found at www.arcellx.com.